M
Marina Sahade
Researcher at University of São Paulo
Publications - 6
Citations - 378
Marina Sahade is an academic researcher from University of São Paulo. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 3, co-authored 3 publications receiving 268 citations.
Papers
More filters
Journal ArticleDOI
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.
Mônica Samuel Avila,Silvia Moreira Ayub-Ferreira,Mauro Rogerio de Barros Wanderley Jr.,Fátima das Dores Cruz,Sara Michelly Gonçalves Brandão,Vagner Oliveira Carvalho Rigaud,Marilia Harumi Higuchi-dos-Santos,Ludhmila Abrahão Hajjar,Roberto Kalil Filho,Paulo M. Hoff,Marina Sahade,Marcela S. M. Ferrari,Romulo Leopoldo de Paula Costa,Max S. Mano,Cecilia Cruz,Maria Cristina Donadio Abduch,Marco Stephan Lofrano Alves,Guilherme Veiga Guimarães,Victor Sarli Issa,Márcio Sommer Bittencourt,Edimar Alcides Bocchi +20 more
TL;DR: In this largest clinical trial of β-blockers for prevention of cardiotoxicity under contemporary ANT dosage, the use of carvedilol resulted in a significant reduction in troponin levels and diastolic dysfunction.
Journal ArticleDOI
Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors
Renata Ferrarotto,Laura Testa,Rachel P. Riechelmann,Marina Sahade,Luiz Tenorio Siqueira,Frederico Costa,Paulo M. Hoff +6 more
TL;DR: The CapOx combination was shown to be active in an unselected population with metastatic NET and may be a good platform for the incorporation of the newer molecular targeted agents being investigated for the treatment of this entity.
Journal ArticleDOI
Cediranib: a VEGF receptor tyrosine kinase inhibitor.
TL;DR: Cediranib is a potent inhibitor of the VEGF family receptor tyrosine kinases, and a new agent in cancer treatment that has shown promising activity in a variety of solid malignancies, in preclinical models and in clinical trials.
Journal ArticleDOI
Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil.
M.M. Queiroz,Karina Perez Sacardo,Maurício Fernando Silva Almeida Ribeiro,Luiza Lara Gadotti,Rodrigo Saddi,L. C. Oliveira,Rudinei Diogo Marques Linck,Marcelo Rocha Cruz,Romualdo Barroso-Sousa,Marina Sahade,Tatiana Strava Correa,Max S. Mano,D. Suzuki,Andrea Kazumi Shimada,Artur Katz +14 more
TL;DR: In this article , the efficacy and tolerability of CDK4/6i in the first-line setting were evaluated in a clinical trial with 142 patients with confirmed HR+/HER2 metastatic breast cancer treated with hormonal therapy in combination with ribociclib and abemaciclib.
Journal ArticleDOI
The addition of PD-1/PD-L1 axis blockade to BRAF and MEK inhibition for advanced melanoma patients harboring BRAF mutations: a systematic review and meta-analysis
Maurício Fernando Silva Almeida Ribeiro,Camila Bragança Xavier,Allan Andresson Lima Pereira,Mariana Scaranti,Luiza Dib Batista Bugiato Faria,Tatiana Strava Correa,Marina Sahade,David Queiroz Borges Muniz,Olavo Feher,Gustavo Fernandes,Artur Katz,Rodrigo Ramella Munhoz +11 more
TL;DR: In this paper , the authors evaluated the efficacy and safety of first-line combination ICI and BRAF/MEK inhibitors (triplets) versus doublets (doublets).